10 лет исследованию ARISTOTLE: итоги и уроки
- Авторы: Остроумова О.Д.1, Буторов В.Н.1, Миронова Е.В.2, Долдо Н.М.2
-
Учреждения:
- ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России
- ЧУЗ «Центральная клиническая больница "РЖД-Медицина”»
- Выпуск: Том 23, № 6 (2021)
- Страницы: 477-484
- Раздел: Статьи
- URL: https://journals.rcsi.science/2075-1753/article/view/95476
- DOI: https://doi.org/10.26442/20751753.2021.6.200991
- ID: 95476
Цитировать
Полный текст
Аннотация
Полный текст
Открыть статью на сайте журналаОб авторах
Ольга Дмитриевна Остроумова
ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России
Email: ostroumova.olga@mail.ru
д-р мед. наук, проф., зав. каф. Москва, Россия
Василий Николаевич Буторов
ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава Россииканд. мед. наук, доц., доц. каф. Москва, Россия
Елена Владимировна Миронова
ЧУЗ «Центральная клиническая больница "РЖД-Медицина”»канд. мед. наук, зав. кардиологическим отд-нием Москва, Россия
Николай Михайлович Долдо
ЧУЗ «Центральная клиническая больница "РЖД-Медицина”»врач-кардиолог, зав. терапевтическим отд-нием Москва, Россия
Список литературы
- Granger CB, Alexander JH, McMurray JJV, et al. for the ARISTOTLE committees and investigators. ARISTOTLE primary results. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-92. doi: 10.1056/NEJMoa1107039
- Drazen’s Dozen: articles that changed practice since 2000. N Engl J Med. Available at: https://cdn. nejm.org/pdf/Drazens-Dozen.pdf. Accessed: 15.06.21.
- Lopes RD, Alexander JH, Al-Khatib SM, et al.; ARISTOTLE Investigators. Apixaban for Reduction In Stroke and other ThromboemboLic Events in atrial fibrillation (ARISTOTLE) trial: design and rationale. 4m Heart J. 2010;159(3):331-9. doi: 10.1016/j.ahj.2009.07.035
- Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in nonsurgical patients. J Thromb Haemost. 2005;3(4):692-4. doi: 10.1111/j.1538-7836.2005.01204.x
- Ottervanger JP, Armstrong P, Barnathan ES, et al.; GUSTO IV-ACS Investigators. Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV--Acute Coronary Syndrome) Trial Global Use of Strategies To Open Occluded Coronary Arteries IV-Acute Coronary Syndrome - GUSTO IV-ACS One Year Follow-up. Circulation. 2003;107(3):437-42. doi: 10.1161/01.cir.0000046487.06811.5e
- Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial - phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988;11(1):1-11. doi: 10.1016/0735-1097(88)90158-1
- Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and tromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124. doi: 10.1136/bmj.d124
- DuGoff EH, Canudas-Romo V, Buttorff C, et al. Multiple chronic conditions and life expectancy: a life table analysis. Med Care. 2014;52(8):688-94. doi: 10.1097/MLR.0000000000000166
- Brambatti M, Darius H, Oldgren J, et al. Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. Int J Cardiol. 2015;196:127-31. doi: 10.1016/j.ijcard.2015.05.141
- De Caterina R, Patti G, Westerbergh J, et al. Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. Eur Heart J Cardiovasc Pharmacother. 2020;pvaa140. doi: 10.1093/ehjcvp/pvaa140
- Ezekowitz JA, Lewis BS, Renato LD, et al. Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. Eur Heart J Cardiovasc Pharmacother. 2015;1:86-94. doi: 10.1093/ehjcvp/pvu024
- Benjamin EJ, Blaha MJ, Chiuve SE, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics - 2017 Update: A Report From the American Heart Association. Circulation. 2017;135:e146-e603. doi: 10.1161/CIR.0000000000000485
- Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33(22):2821-30. doi: 10.1093/eurheartj/ehs274
- Hijazi Z, Hohnloser SH, Andersson U, et al. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. J4M4 Cardiol. 2016;1(4):451-60. doi: 10.1001/jamacardio.2016.1170
- Stanifer JW, Pokorney SD, Chertow GM, et al. Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. Circulation. 2020;28;141 (17):1384-92. doi: 10.1161/CIRCULATIONAHA.119.044059
- Hijazi Z, Granger CB, Hohnloser SH, et al. Association of Different Estimates of Renal Function With Cardiovascular Mortality and Bleeding in Atrial Fibrillation. J Am Heart Assoc. 2020;9:e017155. doi: 10.1161/JAHA.120.017155
- Sandhu RK, Ezekowitz J, Andersson U, et al. The 'obesity paradox’ in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. Eur Heart J. 2016;37(38):2869-78. doi: 10.1093/eurheartj/ehw124
- Hohnloser SH, Fudim M, Alexander JH, et al. Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight Insights From the ARISTOTLE Tria. Circulation. 2019;139:2292-300. doi: 10.1161/CIRCULATIONAHA.118.037955
- Batra G, Svennblad B, Held C, et al. All types of atrial fibrillation in the setting of myocardial infarction are associated with impaired outcome. Heart. 2016;102(12):926-33. doi: 10.1136/heartjnl-2015-308678
- Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806-17. doi: 10.1056/NEJMoa1007432
- Bahit MC, Lopes RD, Wojdyla DM, et al. Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial. Int J Cardiol. 2013;170(2):215-20. doi: 10.1016/j.ijcard.2013.10.062
- Lopes RD, Al-Khatib SM, Wallentin L, et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet. 2012;380(9855):1749-58. doi: 10.1016/S0140-6736(12)60986-6
- Wallentin L, Lopes RD, Hanna M, et al.; ARISTOTLE Investigators. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation. 2013;127:2166-76. doi: 10.1161/CIRCULATIONAHA.114.011204
- Sharma A, Hijazi Z, Andersson U, et al. The use of biomarkers to predict specific causes of death in patients with atrial fibrillation: Insights from the ARISTOTLE trial. Circulation. 2018;138(16):1666-76. doi: 10.1161/CIRCULATIONAHA.118.034125
- Hijazi Z, Wallentin L, Siegbahn A, et al. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol. 2013;61:2274-84. doi: 10.1016/j.jacc.2012.11.082
- Christersson C, Wallentin L, Andersson U, et al. D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation - observations from the ARISTOTLE trial. J Thromb Haemost. 2014;12(9):1401-12. doi: 10.1111/jth.12638
- Horowitz JD, De Caterina R, Heresztyn T, et al.; ARISTOTLE Investigators. Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation: An ARISTOTLE Substudy. J Am Coll Cardiol. 2018;72(7):721-33. doi: 10.1016/j.jacc.2018.05.058
- Aulin J, Hijazi Z, Siegbahn A, et al. Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials. J Thromb Haemost. 2020;18:2287-95. doi: 10.1111/jth.14947
- Hijazi Z, Aulin J, Andersson U et al.; ARISTOTLE Investigators. Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. Heart. 2016;102:508-17. doi: 10.1136/heartjnl-2015-308887
- Hijazi Z, Lindback J, Alexander JH et al.; ARISTOTLE and STABILITY Investigators. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J. 2016;37(20):1582-90. doi: 10.1093/eurheartj/ehw054
- Hijazi Z, Wallentin L, Siegbahn A, et al.; ARISTOTLE Investigators. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. J Am Coll Cardiol. 2014;63:52-61. doi: 10.1016/j.jacc.2013.07.093
- Hijazi Z, Siegbahn A, Andersson U, et al.; ARISTOTLE Investigators. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thrombolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2014;129:625-34. doi: 10.1161/CIRCULATIONAHA.113.006286
- Rosjo H, Hijazi Z, Omland T, et al. Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial. J Intern Med. 2020;288(2):248-59. doi: 10.1111/joim.13072
- Oldgren J, Hijazi Z, Lindback J, et al.; RE-LY and ARISTOTLE Investigators. Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. Circulation. 2016;134(22):1697-707. doi: 10.1161/CIRCULATIONAHA.116.022802
- Hijazi Z, Oldgren J, Lindback J, et al.; ARISTOTLE and RE-LY Investigators. A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. Eur Heart J. 2018;39(6):477-85. doi: 10.1093/eurheartj/ehx584
- Hijazi Z, Oldgren J, Lindback J, et al.; ARISTOTLE and RE-LY Investigators. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016;387(10035):2302-11. doi: 10.1016/S0140-6736(16)00741-8
- Hijazi Z, Oldgren J, Lindback J, et al. Evaluation of the Age, Biomarkers, and Clinical HistoryBleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation. Therapy Enrolled in the ARISTOTLE and RE-LY Trials. JAMA Network Open. 2020;3(9):e2015943. doi: 10.1001/jamanetworkopen.2020.15943
- Vinereanu D, Lopes RD, Mulder H, et al.; ARISTOTLE Investigators. Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin. Stroke. 2017;48(12):3266-73. doi: 10.1161/STROKEAHA.117.017574